In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease - PubMed (original) (raw)
In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease
D M Walsh et al. Biochem J. 2001.
Abstract
In a Flemish kindred, an Ala(692)-->Gly amino acid substitution in the amyloid beta-protein precursor (AbetaPP) causes a form of early-onset Alzheimer's disease (AD) which displays prominent amyloid angiopathy and unusually large senile plaque cores. The mechanistic basis of this Flemish form of AD is unknown. Previous in vitro studies of amyloid beta-protein (Abeta) production in HEK-293 cells transfected with cDNA encoding Flemish AbetaPP have shown that full-length [Abeta(1-40)] and truncated [Abeta(5-40) and Abeta(11-40)] forms of Abeta are produced. In an effort to determine how these peptides might contribute to the pathogenesis of the Flemish disease, comparative biophysical and neurotoxicity studies were performed on wild-type and Flemish Abeta(1-40), Abeta(5-40) and Abeta(11-40). The results revealed that the Flemish amino acid substitution increased the solubility of each form of peptide, decreased the rate of formation of thioflavin-T-positive assemblies, and increased the SDS-stability of peptide oligomers. Although the kinetics of peptide assembly were altered by the Ala(21)-->Gly substitution, all three Flemish variants formed fibrils, as did the wild-type peptides. Importantly, toxicity studies using cultured primary rat cortical cells showed that the Flemish assemblies were as potent a neurotoxin as were the wild-type assemblies. Our results are consistent with a pathogenetic process in which conformational changes in Abeta induced by the Ala(21)-->Gly substitution would facilitate peptide adherence to the vascular endothelium, creating nidi for amyloid growth. Increased peptide solubility and assembly stability would favour formation of larger deposits and inhibit their elimination. In addition, increased concentrations of neurotoxic assemblies would accelerate neuronal injury and death.
Similar articles
- In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity.
Kumar-Singh S, Julliams A, Nuydens R, Ceuterick C, Labeur C, Serneels S, Vennekens K, Van Osta P, Geerts H, De Strooper B, Van Broeckhoven C. Kumar-Singh S, et al. Neurobiol Dis. 2002 Nov;11(2):330-40. doi: 10.1006/nbdi.2002.0529. Neurobiol Dis. 2002. PMID: 12505425 - Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant.
Muñoz FJ, Opazo C, Gil-Gómez G, Tapia G, Fernández V, Valverde MA, Inestrosa NC. Muñoz FJ, et al. J Neurosci. 2002 Apr 15;22(8):3081-9. doi: 10.1523/JNEUROSCI.22-08-03081.2002. J Neurosci. 2002. PMID: 11943811 Free PMC article. - Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.
Kumar-Singh S, Cras P, Wang R, Kros JM, van Swieten J, Lübke U, Ceuterick C, Serneels S, Vennekens K, Timmermans JP, Van Marck E, Martin JJ, van Duijn CM, Van Broeckhoven C. Kumar-Singh S, et al. Am J Pathol. 2002 Aug;161(2):507-20. doi: 10.1016/S0002-9440(10)64207-1. Am J Pathol. 2002. PMID: 12163376 Free PMC article. - Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
Watson D, Castaño E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE. Watson D, et al. Neurol Res. 2005 Dec;27(8):869-81. doi: 10.1179/016164105X49436. Neurol Res. 2005. PMID: 16354549 Review. - [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T. Tomiyama T. Brain Nerve. 2010 Jul;62(7):691-9. Brain Nerve. 2010. PMID: 20675873 Review. Japanese.
Cited by
- Monitoring insulin aggregation via capillary electrophoresis.
Pryor E, Kotarek JA, Moss MA, Hestekin CN. Pryor E, et al. Int J Mol Sci. 2011;12(12):9369-88. doi: 10.3390/ijms12129369. Epub 2011 Dec 14. Int J Mol Sci. 2011. PMID: 22272138 Free PMC article. - Stability of transmembrane amyloid β-peptide and membrane integrity tested by molecular modeling of site-specific Aβ42 mutations.
Poojari C, Strodel B. Poojari C, et al. PLoS One. 2013 Nov 7;8(11):e78399. doi: 10.1371/journal.pone.0078399. eCollection 2013. PLoS One. 2013. PMID: 24244308 Free PMC article. - A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide.
Walsh DM, Thulin E, Minogue AM, Gustavsson N, Pang E, Teplow DB, Linse S. Walsh DM, et al. FEBS J. 2009 Mar;276(5):1266-81. doi: 10.1111/j.1742-4658.2008.06862.x. FEBS J. 2009. PMID: 19175671 Free PMC article. - Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities.
Dorostkar MM, Zou C, Blazquez-Llorca L, Herms J. Dorostkar MM, et al. Acta Neuropathol. 2015 Jul;130(1):1-19. doi: 10.1007/s00401-015-1449-5. Epub 2015 Jun 11. Acta Neuropathol. 2015. PMID: 26063233 Free PMC article. Review. - Overview on the Effects of _N_-Acetylcysteine in Neurodegenerative Diseases.
Tardiolo G, Bramanti P, Mazzon E. Tardiolo G, et al. Molecules. 2018 Dec 13;23(12):3305. doi: 10.3390/molecules23123305. Molecules. 2018. PMID: 30551603 Free PMC article. Review.
References
- Biochem Biophys Res Commun. 1993 Feb 26;191(1):232-9 - PubMed
- Biochemistry. 1992 Nov 10;31(44):10716-23 - PubMed
- J Neurosci. 1993 May;13(5):1993-2000 - PubMed
- Nat Genet. 1992 Jun;1(3):218-21 - PubMed
- Neurosci Lett. 1993 Oct 14;161(1):17-20 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous